BiotechTube

Camrelizumab + Nab paclitaxel + Epirubicin + Cyclophosphamide

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer

Conditions

Triple Negative Breast Cancer

Trial Timeline

May 20, 2020 → Feb 28, 2024

NCT ID
NCT04676997

About Camrelizumab + Nab paclitaxel + Epirubicin + Cyclophosphamide

Camrelizumab + Nab paclitaxel + Epirubicin + Cyclophosphamide is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Triple Negative Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04676997. Target conditions include Triple Negative Breast Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04676997Phase 2UNKNOWN

Competing Products

20 competing products in Triple Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
eFT508eFFECTOR TherapeuticsPhase 2
44
No drugDaiichi SankyoPre-clinical
23
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
Abemaciclib + BicalutamideEli LillyPhase 2
52
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
77
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
65
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
33
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
77
Combination of Veliparib + LapatinibAbbViePre-clinical
23
Capivasertib + ItraconazoleAstraZenecaPhase 1
33
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
52
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
41
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
33
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
77
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
52
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecanAstraZenecaPhase 1/2
41

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85